NOC4L: A Potential Drug Target for Neuronal Excitability (G79050)

Target Name: NOC4L

NCBI ID: G79050

NOC4L

NOC4L: A Potential Drug Target for Neuronal Excitability

NOC4L (NOC4L_HUMAN) is a protein that is expressed in various tissues of the human body, including the nervous system. Its full name is neurofilament-capping protein 4-like, and it is a member of the neurofilament family. This protein is of interest as a potential drug target or biomarker due to its unique structure and the involvement in various physiological processes in the human body.

The neurofilament family is a group of proteins that are characterized by the presence of a specific domain called the neurofilament-capping domain. This domain is responsible for the regulation of the stability and dynamics of the neurofilament protein. NOC4L is a type of neurofilament-capping protein that is characterized by its ability to cap the neurofilament protein and regulate its stability.

One of the key functions of NOC4L is its role in the regulation of neuronal excitability. Neurons are responsible for transmitting electrical signals along the nervous system, and their excitability is regulated by various factors, including the levels of neurotransmitters and the structure of the neuronal synapses. NOC4L is involved in the regulation of these processes by cap

Protein Name: Nucleolar Complex Associated 4 Homolog

The "NOC4L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NOC4L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets